Get the Stockscreener App
1.29
2.27%
-0.03
After Hours:
1.28
-0.01
-0.78%
Iterum Therapeutics Plc stock is traded at $1.29, with a volume of 724.05K.
It is down -2.27% in the last 24 hours and up +28.36% over the past month.
Iterum Therapeutics PLC is a clinical-stage pharmaceutical company. The company is engaged in developing and commercializing sulopenem to be the first and only oral and intravenous branded penem available globally. Its sulopenem program has the potential to offer a solution to the problem of antibiotic resistance and the toxicity limitations of existing agents. The company operates as a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
See More
Previous Close:
$1.32
Open:
$1.27
24h Volume:
724.05K
Relative Volume:
0.32
Market Cap:
$29.29M
Revenue:
-
Net Income/Loss:
$-35.58M
P/E Ratio:
-0.2854
EPS:
-4.52
Net Cash Flow:
$-42.82M
1W Performance:
-11.03%
1M Performance:
+28.36%
6M Performance:
-16.77%
1Y Performance:
+72.00%
1-Day Range:
$1.24
$1.32
1-Week Range:
$1.16
$1.44
52-Week Range:
$0.705
$2.50
Iterum Therapeutics Plc Stock (ITRM) Company Profile
Name
Iterum Therapeutics Plc
Sector
Industry
Phone
(872) 225-6077
Address
FITZWILLIAM COURT, 1ST FLOOR, DUBLIN 2
Iterum Therapeutics Plc Stock (ITRM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-28-21 | Upgrade | Gabelli & Co | Sell → Hold |
| Mar-15-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jun-02-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-21-20 | Downgrade | Gabelli & Co | Buy → Sell |
| Dec-11-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jun-21-19 | Initiated | H.C. Wainwright | Buy |
View All
Iterum Therapeutics Plc Stock (ITRM) Latest News
Iterum Therapeutics defers $20 million FDA milestone payment By Investing.com - Investing.com Australia
Iterum Therapeutics defers $20 million FDA milestone payment - Investing.com India
Iterum Therapeutics : Financial Obligation Form 8 K - Marketscreener.com
ITRMIterum Therapeutics plc Ordinary Share Latest Stock News & Market Updates - StockTitan
FDA Approves Oral Sulopenem (Orlynvah) for Uncomplicated Urinary Tract Infections - Contagionlive.com
Iterum Scores First Approval For Oral Penem Antibiotic - Citeline
Second Oral UTI Treatment Approved, But Still No Vaccine - Precision Vaccinations
Biotech Alert: Searches spiking for these stocks today - TipRanks
FDA Approval Of Orlynvah For Urinary Tract Infections Marks Milestone For Iterum, Paves Way For New Strategic Partnerships - Benzinga
FDA approves Iterum’s ORLYNVAH NDA for uUTI treatment - Pharmaceutical Technology
Iterum Therapeutics to Host Morning Conference Call on U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections - BioSpace
NaoTrac to Redefine Surgical Navigation Robotics at MEDICA 2024 - Lelezard
Iterum stock rallies 54% on FDA approval of Orlynvah for UTIs - MSN
Major Improvements In Iterum Therapeutics Plc (ITRM) Stock Need To Be Considered - Stocks Register
FDA approves new oral antibiotic ORLYNVAH for uUTIs By Investing.com - Investing.com Nigeria
Iterum Therapeutics (ITRM) Scores FDA Approval for New UTI Drug ORLYNVAH™ - BP Journal
Allovir (ALVR) Sees 5.06% Stock Price Surge Amid Mixed Analyst R - GuruFocus.com
Wall Street-Heavily Traded - WDRB
Iterum Therapeutics Shares Soar on FDA's Orlynvah Approval - Marketscreener.com
FDA approves new oral antibiotic ORLYNVAH for uUTIs - Investing.com India
Iterum Therapeutics Gains FDA Approval for ORLYNVAH - TipRanks
US FDA approves Iterum's treatment for urinary infection - Reuters.com
Iterum Therapeutics announces FDA approval of Orlynvah - TipRanks
Iterum Therapeutics Receives U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections - The Manila Times
Week Ahead (Jul.26-30): INFI To Provide Update On Eganelisib Trials, Writing's On The Wall For ITRM? - RTTNews
Renaissance Technologies LLC Trims Stock Holdings in Iterum Therapeutics plc (NASDAQ:ITRM) - Defense World
Iterum Therapeutics to Present Data at IDWeek 2024 - StockTitan
Iterum Therapeutics to Participate at the 2024 Maxim Healthcare Virtual Summit - The Manila Times
Iterum Therapeutics shareholders approve share issuance authority - Investing.com
Iterum Therapeutics shareholders approve share issuance authority By Investing.com - Investing.com Canada
Iterum Therapeutics faces Nasdaq delisting over equity shortfall - Investing.com India
Iterum Therapeutics faces Nasdaq delisting over equity shortfall By Investing.com - Investing.com UK
Biotech Stocks Facing FDA Decision In October 2024 - RTTNews
IDWeek 2022 PresentationsIVVD, SPRO, INVA, CDTX, ANTX, GSK - RTTNews
Nothing is Better Than Iterum Therapeutics Plc (ITRM) stock at the moment - SETE News
ITRM Posts Updates From FDA Advisory Meeting for UTI Drug, Stock Down - Yahoo Finance
Iterum Therapeutics’ (ITRM) Buy Rating Reaffirmed at HC Wainwright - Defense World
Iterum's oral antibiotic discussed at FDA advisory meeting - Investing.com India
Iterum stock falls 9% in wake of FDA AdComm meeting on UTI drug - MSN
A closer look at ITRM’s price-to-free cash flow ratio - US Post News
Iterum stock falls 9% in wake of FDA AdComm meeting on UTI drug (NASDAQ:ITRM) - Seeking Alpha
Iterum's oral antibiotic discussed at FDA advisory meeting By Investing.com - Investing.com Canada
Iterum Therapeutics Provides Update on FDA Advisory Committee Discussion of Oral Sulopenem for the Treatment - EIN News
Iterum Therapeutics Plc (ITRM)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex
FDA Advisory Committee meets to discuss NDA of oral sulopenem for uUTI - Urology Times
Iterum Therapeutics to Present at the 26th Annual H.C. Wainwright Global Investment Conference - StockTitan
Iterum Therapeutics Plc (ITRM)’s highs and lows: A closer look at its stock price fluctuations - US Post News
Iterum Therapeutics Plc Stock (ITRM) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):